Tetracyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 514/284)
-
Publication number: 20140287918Abstract: Use of a Peumus Boldus extract obtained by in vitro culture, with antibotricide, allelochemical and antioxidant capacity.Type: ApplicationFiled: October 19, 2012Publication date: September 25, 2014Inventor: Gustavo Zuniga
-
Publication number: 20140271845Abstract: Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Applicant: Cerovene, Inc.Inventors: Manish S. SHAH, Ray J. DiFalco
-
Publication number: 20140256627Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.Type: ApplicationFiled: February 4, 2014Publication date: September 11, 2014Applicant: Massachusetts Eye and Ear InfirmaryInventor: Benjamin S. Bleier
-
Patent number: 8828988Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.Type: GrantFiled: December 31, 2012Date of Patent: September 9, 2014Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Roger B. Clark, Minsheng He, Louis Plamondon, Xiao-Yi Xiao, Magnus P. Rönn
-
Patent number: 8829022Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: GrantFiled: October 11, 2011Date of Patent: September 9, 2014Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
-
Patent number: 8829023Abstract: The invention relates to a process for obtaining compounds derived from tetrahydro-?-carboline, specifically tadalafil and intermediate products from the synthesis, comprising the reaction between piperonal and an alkyl ester of D-tryptophan as a salt, and in the absence of any other component, followed by haloacetylation and a final cyclization with methylamine.Type: GrantFiled: February 10, 2012Date of Patent: September 9, 2014Assignee: Interquim, S.A.Inventors: Xavier Berzosa Rodríguez, Francisco Marquillas Olondriz
-
Patent number: 8822442Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.Type: GrantFiled: October 28, 2005Date of Patent: September 2, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
-
Publication number: 20140228355Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.Type: ApplicationFiled: February 11, 2013Publication date: August 14, 2014Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, University of Medicine and Dentistry New Jersey Medical School
-
Publication number: 20140194450Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.Type: ApplicationFiled: January 10, 2013Publication date: July 10, 2014Applicant: ALLERGAN, INC.Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
-
Publication number: 20140194459Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.Type: ApplicationFiled: March 5, 2014Publication date: July 10, 2014Applicant: Vanda Pharmaceuticals, Inc.Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
-
Patent number: 8772309Abstract: The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function.Type: GrantFiled: November 5, 2012Date of Patent: July 8, 2014Assignee: Amarin Pharmaceuticals Ireland LimitedInventor: Anthony Clarke
-
Publication number: 20140179653Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.Type: ApplicationFiled: October 11, 2013Publication date: June 26, 2014Applicants: APR APPLIED PHARMA RESEARCH SA, LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBHInventors: Christian Leichs, Armin Breitenbach, Ingo Lehrke, Paolo Galfetti
-
Patent number: 8741917Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.Type: GrantFiled: January 15, 2010Date of Patent: June 3, 2014Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
-
Publication number: 20140128422Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: Britannia Pharmaceuticals Ltd.Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
-
Patent number: 8710071Abstract: The present technology relates to compounds of Formulas (V) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.Type: GrantFiled: December 22, 2009Date of Patent: April 29, 2014Assignee: CVI Pharmaceuticals LimitedInventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu
-
Patent number: 8691814Abstract: The present invention provides compounds having formula (I): wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.Type: GrantFiled: November 2, 2010Date of Patent: April 8, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Patent number: 8691801Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.Type: GrantFiled: July 17, 2012Date of Patent: April 8, 2014Assignee: Florida Atlantic University Board of TrusteesInventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
-
Patent number: 8686146Abstract: The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.Type: GrantFiled: July 13, 2012Date of Patent: April 1, 2014Assignee: Purdue Research FoundationInventors: Mark S. Cushman, Evgeny A. Kiselev, Andrew E. Morrell
-
Publication number: 20140088130Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Hong LIU, Xin XIE, Xuechu ZHEN, Haifeng SUN, Jing LI, Liyuan ZHU, Zeng LI, Ying CHEN, Hualiang JIANG, Kaixian CHEN
-
Patent number: 8664238Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.Type: GrantFiled: December 16, 2009Date of Patent: March 4, 2014Assignees: China Pharmaceutical University, Nanjing Medical University Affiliated Brain HospitalInventors: Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
-
Patent number: 8664395Abstract: The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with high yield and productivity. In particular, the present invention relates to a process for the separation of 4-aza-androstan-17-oic acid from 4-aza-androst-1-ene-17-oic acid, comprising the steps of treating the crude 4-aza-androst-1-ene-17-oic acid with formic acid and recovering the purified 4-aza-androst-1-ene-17-oic acid containing 4-aza-androstan-17-oic acid in w/w % less than 0.05%.Type: GrantFiled: April 2, 2009Date of Patent: March 4, 2014Assignee: PHF S.A.Inventors: Mauro Bonetti, Sabrina De Rosa
-
Publication number: 20140037710Abstract: A method for producing a patch including a support layer and an adhesive layer, comprising the step of forming the adhesive layer with use of an adhesive layer composition obtained by mixing an alkali metal diacetate, a drug, and a nonaqueous adhesive base such that the molar ratio between the drug and the alkali metal diacetate (the number of moles of the drug:the number of moles of the alkali metal diacetate) is from 1:0.5 to 1:15.Type: ApplicationFiled: April 12, 2012Publication date: February 6, 2014Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Eiji Hashimoto, Isao Hagiwara, Yukihisa Naka, Hideharu Chono
-
Publication number: 20140023653Abstract: The present invention provides compositions comprising a compound of Formula I, and salts, hydrates, and isomers thereof. Methods of promoting bone formation and/or bone growth, treating renal disease, and treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I, are also provided. Medical devices comprising a compound of Formula I are also provided.Type: ApplicationFiled: July 16, 2013Publication date: January 23, 2014Inventors: Debra Ellies, Ferris Scott Kimball
-
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
Patent number: 8618123Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.Type: GrantFiled: July 15, 2008Date of Patent: December 31, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien -
Patent number: 8618299Abstract: MCH-1 receptor antagonists are disclosed having the general formula These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: GrantFiled: July 1, 2010Date of Patent: December 31, 2013Assignee: Albany Molecular Research, Inc.Inventors: Peter R. Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang
-
Publication number: 20130345252Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.Type: ApplicationFiled: March 15, 2013Publication date: December 26, 2013Inventors: MARK S. CUSHMAN, TRUNG X. NGUYEN, MARTIN M. CONDA-SHERIDAN
-
Publication number: 20130345230Abstract: The present invention relates to methods and compositions for modulating calcium channels. In particular, the present invention provides methods and compositions for modulating (e.g., disrupting) Cav1.3a calcium channels for research and therapeutic methods (e.g., treating dopaminergic diseases and conditions).Type: ApplicationFiled: August 27, 2013Publication date: December 26, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: D. James Surmeier, Michelle Day, Jun Ding, Savio Chan, Jamie Guzman, Jeff Mercer, Tatiana Tkatch, Zhongfeng Wang, Ema Ilijic
-
Publication number: 20130345164Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.Type: ApplicationFiled: April 21, 2011Publication date: December 26, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
-
Patent number: 8604047Abstract: Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5?-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of acne vulgaris. Very high dosages of such compounds can effectively be administered oral just once a week and be successful.Type: GrantFiled: August 10, 2010Date of Patent: December 10, 2013Assignee: Elorac, Inc.Inventor: Joel E. Bernstein
-
Publication number: 20130324508Abstract: The present invention relates to a biomarker for characterizing prostate cancer and method of using the same. More particularly, the invention relates to method of using a membrane-associated C family G protein-coupled receptor GPRC6A as biomarker of characterizing prostate cancer progression. The present invention also provides a kit for detecting prostate cancer in a subject.Type: ApplicationFiled: June 3, 2013Publication date: December 5, 2013Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Leigh Darryl Quarles, Min Pi
-
Patent number: 8592424Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.Type: GrantFiled: June 29, 2009Date of Patent: November 26, 2013Assignee: Afgin Pharma LLCInventor: Ronald Aung-Din
-
Patent number: 8580773Abstract: The present invention provides tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof. The present invention provides a method of using tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof.Type: GrantFiled: December 6, 2012Date of Patent: November 12, 2013Assignee: The Regents of the University of CaliforniaInventors: Marc I. Diamond, Jeremy O. Jones, Adam R. Renslo
-
Publication number: 20130296279Abstract: The invention in one embodiment is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to a composition comprising the compound of formula I or a pharmaceutically acceptable salt, and methods of treating the indications listed herein.Type: ApplicationFiled: May 10, 2013Publication date: November 7, 2013Inventor: Adam Morgan
-
Patent number: 8575165Abstract: Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I):Type: GrantFiled: January 13, 2010Date of Patent: November 5, 2013Assignee: Rigel Pharmaceuticals, Inc.Inventors: Tarikere Gururaja, Donald G. Payan, Kin Tso, Taisei Kinoshita, Rongxian Ding, Rajinder Singh, Stephanie Yung, Hui Li, Esteban Masuda
-
Publication number: 20130287854Abstract: According to the invention there is provided a method of treating and/or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and/or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation.Type: ApplicationFiled: November 15, 2011Publication date: October 31, 2013Applicant: VECTURA LIMITEDInventors: Frazer Giles Morgan, Mark Jonathan Main
-
Publication number: 20130261146Abstract: A pharmaceutical composition for stimulating nitric oxide production in mammalian cells, the pharmaceutical composition including at least one compound selected from a group consisting of: 2,3-dihydroxypropyl oleate; bis(m-phenoxyphenyl) ether; 6-acetyl-5,6,6a,7-tetrahydro-4H-dibezo(de,g)quinoline; and (+)-N-(p-(2-methylbutoxy)benzylidene)-4-(2-methylbutyl)aniline.Type: ApplicationFiled: December 9, 2010Publication date: October 3, 2013Applicant: The Research Foundation of State University of New YorkInventors: George B. Stefano, Wei Zhu, Kirk Mantione, Richard M. Kream
-
Publication number: 20130252983Abstract: A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed.Type: ApplicationFiled: September 12, 2011Publication date: September 26, 2013Applicant: CORNELL UNIVERSITYInventors: Kristin Wilson Cerione, Richard A. Cerione
-
Publication number: 20130251647Abstract: The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.Type: ApplicationFiled: September 20, 2012Publication date: September 26, 2013Applicant: BASF SEInventors: Thomas Subkowski, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel, Ralf Pelzer
-
Publication number: 20130237524Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.Type: ApplicationFiled: March 7, 2013Publication date: September 12, 2013Applicant: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Donald G. Payan, Sylvia Braselmann
-
Patent number: 8530493Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.Type: GrantFiled: February 21, 2007Date of Patent: September 10, 2013Assignee: 4SC AGInventors: Matthias Vennemann, Thomas Bãr, Jürgen Braunger, Astrid Zimmermann, Volker Gekeler
-
Publication number: 20130231311Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. SCHUSTER
-
Publication number: 20130225626Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.Type: ApplicationFiled: April 8, 2013Publication date: August 29, 2013Applicants: ARx, LLC, Cynapsus Therapeutics, Inc.Inventors: Cynapsus Therapeutics, Inc., ARx, LLC
-
Publication number: 20130217685Abstract: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.Type: ApplicationFiled: January 8, 2013Publication date: August 22, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventor: University of Massachusetts
-
Patent number: 8513274Abstract: The present invention provides a method of reducing body weight in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I: In Formula I, R1 is H, C1-6 alkyl, or C1-6 alkyl-aryl. Each of R2 and R4 of Formula I are independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkoxy, —OR2a, —SR2a, —C(O)R2a, —C(O)OR2a, —C(O)NR2aR2b, —NR2aR2b, C1-6 alkyl-NR2aR2b, —N(R2a)C(O)R2b, —N(R2a)C(O)OR2b, —N(R2a)C(O)NR2aR2b, —OP(O)(OR2a)2, —S(O)2OR2a, —S(O)2NR2aR2b, —CN, —NO2, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. Each of R2a and R2b of Formula I are independently H, C1-6 alkyl, C1-10 heteroalkyl or C1-6 alkyl-aryl. R3 of Formula I is absent, C1-6 alkyl or N-oxide. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of obesity and disorders related to obesity and higher than recommended percentage body fat, such as type II diabetes.Type: GrantFiled: March 15, 2010Date of Patent: August 20, 2013Assignee: Etzem, Inc.Inventors: Debra Ellies, William Rosenberg
-
Publication number: 20130209362Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.Type: ApplicationFiled: April 14, 2011Publication date: August 15, 2013Applicant: The McLean Hospital CorporationInventors: John L. Neumeyer, Yu-Gui Si, Anna W. Sromek
-
Patent number: 8501762Abstract: The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia.Type: GrantFiled: July 7, 2006Date of Patent: August 6, 2013Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Topharman Shanghai Co., Ltd.Inventors: Jianfeng Li, Aixiang Liu, Xinjian Chen, Guozhang Jin, Tiema Yan, Rongxia Zhang, Yi Zhu, Yanjun Pan, Jingshan Shen, Jingkang Shen
-
Publication number: 20130196956Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Publication number: 20130190321Abstract: Methods and kits for aiding in detection, assessment and treatment of a proliferative disorder of the prostate gland in a subject are provided according to aspects of the present invention which include assaying a first biological sample comprising prostate gland cells obtained from the subject for expression of one or more biomarkers selected from the group consisting of: alcohol dehydrogenase 1B, alcohol dehydrogenase 1C, alcohol dehydrogenase 4 and hepatocyte nuclear factor 1B; and determining, based on the expression of the one or more biomarkers in the sample that the subject has, or is at risk of having, a proliferative disorder of the prostate gland.Type: ApplicationFiled: January 23, 2013Publication date: July 25, 2013Applicant: WEST CHESTER UNIVERSITY OF PENNSYLVANIAInventor: West Chester University of Pennsylvania
-
Patent number: 8486959Abstract: A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection.Type: GrantFiled: January 14, 2011Date of Patent: July 16, 2013Assignee: National Health Research InstitutesInventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee, Yu-Sheng Chao
-
Patent number: 8481557Abstract: Methods of treating cancer by administering a DNA damaging agent and a CHK1 Inhibitor on a dosing regimen are provided.Type: GrantFiled: April 9, 2010Date of Patent: July 9, 2013Assignee: Array Biopharma Inc.Inventors: Michael J. Humphries, Shannon L. Winski